Drug Search Results
More Filters [+]

Tyzivumab

Alternative Names: tyzivumab, ty-008, ty008, ty 008
Latest Update: 2022-03-24
Latest Update Note: Clinical Trial Update

Product Description

Tyzivumab is a first-in-class monoclonal antibody designed and engineered to neutralize Zika virus by binding to a specific quaternary epitope of the envelope (E) protein on virus surface. (Sourced from: https://www.tychan.com)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Antibody

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Tychan Pte Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tyzivumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Zika Virus Infection

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ZKT-002

P1

Withdrawn

Zika Virus Infection

2022-01-05

70%

ZKT-001

P1

Completed

Zika Virus Infection

2018-09-12

22%

Recent News Events